Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyltransferase-like protein 27 (METTL27, also known as WBSCR27) is a protein encoded by a gene frequently deleted in Williams-Beuren syndrome, a multisystem developmental disorder. Structurally, METTL27 is a Class I SAM-dependent methyltransferase with a canonical Rossmann fold, showing biochemical capacity to bind cofactors such as S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH)[1][2]. Despite extensive structural analyses, its substrate—whether nucleic acid, protein, or small molecule—remains unidentified, and no direct biological partners have been validated. The protein is hypothesized to function as a standalone methyltransferase. METTL27 is not implicated in rRNA methylation, histone modification, or protein methylation based on available experimental results[1]. Its role in disease, especially Williams-Beuren syndrome, is unexplored beyond genomic deletion association, and there is no evidence for its utility as a drug target, biomarker, or safety concern at this time[5].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyltransferase-like protein 27 (METTL27).